Rahul D. Ballal
CIK 1805097 · Chief Executive Officer · last filed 2026-06-23
Rahul D. Ballal is a Chief Executive Officer who has filed 32 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for AGIO, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$3.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $561.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
205 PARK ROAD
BURLINGAME, CA 94010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGIO | Director | 15,230 | $36.85 | $561.2K | -$1.12M | 10 | 2026-06-23 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 32,761 | $14.59 | $478.0K | -$2.56M | 16 | 2026-02-17 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | AGIO | Mixed | +2,816 | $0 | EDGAR |
| 2026-02-17 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-08-13 | AGIO | Exer (M) | +2,302 | $0 | EDGAR |
| 2025-06-23 | AGIO | Mixed | +2,120 | $0 | EDGAR |
| 2025-02-10 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-11-12 | AGIO | Mixed | — | -$597.3K | EDGAR |
| 2024-11-08 | AGIO | Notice (144) | −10,000 | -$581.9K | EDGAR |
| 2024-11-07 | AGIO | Notice (144) | −10,000 | -$535.2K | EDGAR |
| 2024-10-10 | Enliven Therapeutics, Inc. (IMRA) Delisted | Mixed | — | -$146.6K | EDGAR |
| 2024-10-08 | ELVN | Notice (144) | −10,420 | -$286.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.